Uterine sarcoma (leiomyosarcoma)
Exam relevance: in 7 of more than 150 board exam reports · rank 88
- Specialty
- Gynaecology · Uterus & endometrium
- Images
- Endoscopy & gross 2
- Exam relevance
- 7 of more than 150 reports · rank 88
- In the app
- 1 flashcard · GynFuchs
- Last updated
- 10/2026 · Dr. Pascal Bafteh
Contents
Images (2)
Endoscopy & gross
Endoscopy & grossDefinition
- Uterine sarcomas are rare malignant mesenchymal tumours of the uterus; leiomyosarcoma arises from smooth muscle cells or their mesenchymal precursors.
Classification
- Leiomyosarcoma is the most common subtype; others are low-grade and high-grade endometrial stromal sarcoma, undifferentiated uterine sarcoma and adenosarcoma.
- Carcinosarcomas are of epithelial origin and are no longer regarded as uterine sarcomas.
Occurrence & epidemiology
Risk
- Sarcoma risk: A finding clinically classified as a fibroid conceals a sarcoma in the order of approximately 0.2 to 0.3 percent.
- Risk factors: The risk increases with age and is significantly higher after menopause.
- Entities: The most common entity is leiomyosarcoma, in addition to endometrial stromal sarcoma and undifferentiated sarcoma.
- Origin: A leiomyosarcoma usually arises de novo and not from a pre-existing fibroid.
Epidemiology and risk factors
- Uterine sarcomas account for about 3–7% of all uterine malignancies.
- Incidence is higher from the age of 50 than in younger women and about twice as high in women of Afro-Caribbean descent as in white women.
Clinical features
- Symptoms are often non-specific: lower abdominal or pelvic pain, abdominal distension and, most commonly, abnormal vaginal bleeding.
- A rapidly growing presumed fibroid in a peri- or postmenopausal woman is suspicious; malignancy is often only recognised on histology.
Histology
- Leiomyosarcoma is distinguished from leiomyoma morphologically by mitoses, atypia and necrosis.
- Spindle cells in intersecting fascicles with co-expression of SMA, desmin and h-caldesmon are typical.
Diagnosis
What Raises Suspicion
- Clinical signs: Suspicious signs are rapid growth progression, growth after menopause, pain, and bleeding.
- Sonography: Sonographic indicators are inhomogeneity with necrotic zones, an indistinct border, and disordered, strong central vascularisation.
- Imaging: The crucial statement on imaging is: neither ultrasound nor MRI can reliably rule out a sarcoma.
- Laboratory tests: In terms of laboratory chemistry, there is no useful marker.
- Ultrasound and MRI cannot yet reliably distinguish a leiomyoma from a sarcoma; the diagnosis is histological.
- FIGO staging for uterine sarcomas has been adapted to the histological subtype.
Treatment principles
- The standard is total hysterectomy with removal of the uterus intact; morcellation must be avoided because it worsens the prognosis.
- Removal of the adnexa is decided according to age and tumour type, and systematic lymphadenectomy is not required if the lymph nodes appear normal.
- Further treatment is decided individually in a tumour board, ideally with sarcoma expertise; in advanced disease, chemotherapy and, for certain subtypes, endocrine therapy are considered.
Specific treatment regimens with drugs and doses are covered in the GynFuchs app.
Keep learning in the app
Further reading (selection)
Cross-references
Keep learning
Keep learning with flashcards, exam questions and spot diagnoses in the GynFuchs app – free, in your browser or as an app.
Related pages: Asherman syndrome · Endometrial hyperplasia · Endometrial cancer
Note: Learning content from the GynFuchs app (flashcards, exam questions, image cases) for medical education – not a treatment recommendation and no substitute for diagnosis or treatment decisions in individual cases. Treatment and management are deliberately not covered on this page.